Silence Therapeutics

Our Pipeline

Our pipeline is based on our proprietary mRNAi GOLD™ Platform designed to precisely target and silence disease-associated genes expressed in the liver, which represents a substantial opportunity. Through this approach, we are developing a pipeline of wholly-owned programs and partnership programs focused in areas of significant unmet need.

Picture1.png (3) Picture1.png (3)

Our technology

We have developed proprietary stabilizing chemistries to improve the robustness of siRNA sequences, together with advanced delivery systems that enable us to specifically target relevant cell types. This results in potent and highly specific product candidates.